Pharmacologic aspects of a phlebotropic drug in CVI-associated edema

Angiology

Volumn 51, Issue 1, 2000, Pages 19-23

  Ramelet, Albert Adrien ^a  

^a NONE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

COUMARIN DERIVATIVE; DAFLON; DIOSMETIN; FLAVONE DERIVATIVE; PYCNOGENOL; PYRONE DERIVATIVE; RUTOSIDE; SAPONIN DERIVATIVE; VASOACTIVE AGENT;

BLOOD VESSEL PERMEABILITY; CHRONIC VEIN INSUFFICIENCY; CONFERENCE PAPER; DRUG EFFICACY; DRUG MECHANISM; HUMAN; LEG EDEMA; LYMPHEDEMA; MICROCIRCULATION;

EID: 0033979208     PISSN: 00033197     EISSN: None     Source Type: Journal    
DOI: 10.1177/000331970005100105     Document Type: Conference Paper

References (21)

1. Ramelet AA: Therapeutic strategy in venous disease: Value of phlebotropic drugs. Phlebolymphology 19:3-7, 1998.
2. Ramelet AA, Monti M: Phlébologie. Masson 1999, 4th éd.
3. Johnston AM, Paul HJ, Young CG: Effets de la micronisation sur l'absorption digestive de la diosmine. Angiologie 50:81-83, 1998.
4. Cospite M, Dominici A: Avantages de la micronisation de Daflon 500 mg par rapport à une diosmine simple dans le traitment de l'insuffisance veineuse. Etude en double aveugle. Phlébologie 51:243-247, 1998.
5. Jutteau J, Bakri F, Pomies P, et al: The human saphenous vein in pharmacology: Effect of a new micronized flavonoidic fraction (Daflon 500 mg) on norepinephrine-induced contraction. Int Angiol 14:8-13, 1995.
6. Duhault J, Pillion G: Mécanisme d'action de Daflon 500 mg sur le tonus veineux noradrénergique. Artères Veines 11:217-218, 1992.
7. Amiel M, Barbe R: Etude de l'activité pharmacodynamique de Daflon 500 mg. Ann Cardio Angeiol (Paris). 47:185-188, 1998.
8. Ibegbuna V, Nicolaides AN, Sowade O, et al: Venous elasticity after treatment with Daflon 500 mg. Angiology 48:45-49, 1997.
9. Bouskela E, Donyo KA, Verbeuren TJ: Effects of Daflon 500 mg on increased microvascular permeability in normal hamsters. Int J Microcirc 15 (suppl 1):22-26, 1995.
10. Galley P, Thiollet M: A double-blind, placebo-controlled trial of a new venoactive flavonoid fraction (Daflon 500 mg) in the treatment of symptomatic capillary fragility. Int Angiol 12:69-72, 1993.
11. 99m red cells. Int Angiol 7:35-38, 1988.
12. Nolte D, Pickelman S, Schütze E, et al: Effects of Daflon® 500 mg on postischemic macromolecular leak syndrome in striated skin muscle of the hamster. Int J Microcirc 17:6-9, 1997.
13. Korthuis RJ, Gute DC: Postischemic leukocyte/endothelial cell interactions and microvascular barrier dysfunction in skeletal muscle: Cellular mechanisms and effect of Daflon 500 mg. Int J Microcirc 17:11-17, 1997.
14. Takase S, Delano FA, Lerond L, et al: Inflammation in chronic venous insufficiency: Is the problem insurmountable? J Vasc Res 36 (suppl):3-10, 1999.
15. Shoab SS, Porter J, Scurr JH, et al: Endothelial activation response to oral micronised flavonoid therapy in patients with chronic venous disease - a prospective study. Eur J Vasc Endovasc Surg 17:313-318, 1999.
16. Casley-Smith JR, Casley-Smith Judith R: Pharmacological activity of Daflon 500 mg on experimental lymphoedema. Lymphology 31 (suppl):7-10, 1997.
17. Cotonat J: Activité lymphaguogue de Daflon 500 mg in vivo chez les chiens. Concilia Med 7:17-21, 1988.
18. McHale NG, Hollywood MA: Control of lymphatic pumping: Interest of Daflon 500 mg. Phlebology 9 (suppl 1):23-25, 1994.
19. Allegra C, Bartolo M. Jr, Carioti B, et al: Microlymphography: Assessment of Daflon 500 mg activity in patients with chronic venous insufficiency. Lymphology 31 (suppl):12-16, 1997.
20. Pecking AP, Floiras JL, Rambert P, et al: Effect of Daflon 500 mg on lymphedema secondary to breast cancer treatment. Lymphology 31 (suppl):25-28, 1997.
21. Laurent R, Gilly R, Frileux C: Clinical evaluation of a venotronic drug in man. Int Angiol 7:39-43, 1988.